Parlux reports lower Q2 as profits and sales slide

By Simon Pitman

- Last updated on GMT

Related tags Company Stock

Parlux has reported another disappointing quarter, with profits
falling 20 per cent against a slight slip in sales, as lower
margins and royalty payments bite hard.

The company said that sales for the quarter ending September 30 were approximately $39.1m, compared to sales of $39.3m for the same period last year, a fall of around 1 per cent.

Net income came in at $3.5m, down from $4.4m, which, as well as being attributed to lower royalties for non-fragrance products, was also blamed on duplicated warehouse and temporary storage expenses, as well as additional interest expenses.

The company also added that some of the costs were offset by a $1.8m gain from the sale of its investment in E com Ventures, a company that is owned by Parlux stakeholder Glen Nussdorf.

Nussdorf has stated his opposition to recent executive board decisions at Parlux and had tried to launch a take-over bid for the company in October last year.

Net sales for the six month period to September 30 came in at $79.8m, compared to $73.1m for the same period a year earlier - an increase of 9 per cent.

For the same period the company reported a net loss of $10.6m, compared to a net profit of $8.3m a year earlier. It said that this figure was largely attributable to a $16.2m compensation charge relating to outstanding warrants issued as a result of a stock split.

The company also said that a review of its financial results for the period ending September 30 , 2006, will be delayed. Although it did not specify a date for its publication, the company blamed a class action suit filed against it on November 8 by shareholders regarding its accountancy practices as the reason for the delay.

Meanwhile, the board of directors says it has authorized a stock buy-back program, that will involve the sale of up to ten million company shares, in step with successive buy-back schemes that have been initiated during the course of the past ten years.

Further to this, a date of February 1, 2007, has been given for NASDAQ to respond to the company's request for a hearing before a panel regarding the filing of the company's previous quarterly results, up to June 30, 2006.

Related news

Show more

Related products

show more

Get up to $500 off IGEN™ Non-GMO Tested Program!

Get up to $500 off IGEN™ Non-GMO Tested Program!

Content provided by SGS Nutrasource | 04-Jul-2024 | Insight Guide

The cosmetics industry has seen unprecedented growth in recent years, and with this growth comes a rising concern for what’s inside our everyday products.

Calendula Cellular Elixir: Alchemy in a cell

Calendula Cellular Elixir: Alchemy in a cell

Content provided by Naolys | 07-Jun-2024 | Product Brochure

Get ready to experience a cellular evolution in skincare with InnerLift Calendula's advanced Plant Cell biotechnology.

Exosomes: Passing Trend or Transformative Reality?

Exosomes: Passing Trend or Transformative Reality?

Content provided by Naolys | 26-Mar-2024 | White Paper

Exosomes, microscopic vesicles naturally present in abundance within Plant Cells, have garnered significant attention within the scientific and cosmetic...

Related suppliers

Follow us

Products

View more

Webinars